Skip to content

CT-Free Electromagnetic Navigation Percutaneous Localization for Pulmonary Nodules Undergoing Sublobar Resection

Clinical Evaluation of CT-Free Electromagnetic Navigation Percutaneous Localization System for Pulmonary Nodules Undergoing Sublobar Resection: A Multicenter Observational Cohort Study

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT07743775
Enrollment
153
Registered
2026-08-04
Start date
2025-06-24
Completion date
2026-03-28
Last updated
2026-08-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Early-Stage Lung Cancer, Pulmonary Nodules

Brief summary

Pulmonary nodules, particularly small and non-palpable nodules, present challenges for accurate localization during sublobar lung resection. This multicenter observational cohort study evaluated the feasibility, accuracy, and safety of CT-Free electromagnetic navigation percutaneous localization for pulmonary nodules requiring sublobar resection. Patients who underwent CT-Free electromagnetic navigation localization were compared with patients who received conventional CT-guided localization. The primary outcome was localization success rate, defined as the distance between the localization marker and the pulmonary nodule center being within 10 mm. Secondary outcomes included localization procedure time, conversion rate to other localization methods, surgical success rate, perioperative complications, postoperative hospitalization duration, and medical resource utilization.

Interventions

None listed

Sponsors

Jianle Chen
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. Adults aged 18 years or older. 2. Patients with pulmonary nodules requiring sublobar resection. 3. Non-palpable pulmonary nodules requiring preoperative localization. 4. Patients undergoing CT-Free electromagnetic navigation localization or CT-guided localization.

Exclusion criteria

1. Central pulmonary nodules unsuitable for localization. 2. Patients unable to undergo sublobar resection. 3. Patients with severe cardiopulmonary dysfunction or major organ dysfunction. 4. Pregnancy or breastfeeding. 5. Patients participating in other clinical trials.

Design outcomes

Primary

MeasureTime frameDescription
Proportion of Participants With Successful Localization Based on Marker-to-Nodule Distance ≤10 mmImmediately after surgical resectionThe proportion of participants with successful pulmonary nodule localization, defined as a distance between the localization marker and the pulmonary nodule center of ≤10 mm, measured by postoperative pathological specimen evaluation.

Secondary

MeasureTime frameDescription
Proportion of Participants Requiring Additional Localization ProceduresDuring surgeryThe proportion of participants requiring additional localization methods because of unsuccessful or inaccurate initial localization.
Number of Participants With Procedure-Related ComplicationsWithin 30 days after surgeryProcedure-related complications including pneumothorax, pulmonary hemorrhage, and infection occurring after localization and surgery.
Duration of Pulmonary Nodule Localization ProcedureFrom initiation to completion of the localization procedureThe duration from initiation of localization preparation to completion of marker placement.
Mean Distance Between Localization Marker and Pulmonary Nodule Center (mm)Immediately after surgical specimen resectionThe mean distance between the localization marker and the pulmonary nodule center measured immediately after surgical specimen resection.
Mean Duration of Postoperative Hospital StayUp to 30 days after surgical resectionThe mean duration of hospitalization after surgical resection, calculated from the date of surgery to the date of hospital discharge.

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Aug 5, 2026